MX2024000591A - Metodos de tratamiento de enfermedades neurologicas. - Google Patents
Metodos de tratamiento de enfermedades neurologicas.Info
- Publication number
- MX2024000591A MX2024000591A MX2024000591A MX2024000591A MX2024000591A MX 2024000591 A MX2024000591 A MX 2024000591A MX 2024000591 A MX2024000591 A MX 2024000591A MX 2024000591 A MX2024000591 A MX 2024000591A MX 2024000591 A MX2024000591 A MX 2024000591A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- neurological diseases
- treating neurological
- antibodies
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221261P | 2021-07-13 | 2021-07-13 | |
| PCT/CN2022/105077 WO2023284710A1 (en) | 2021-07-13 | 2022-07-12 | Methods of treating neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000591A true MX2024000591A (es) | 2024-03-19 |
Family
ID=84919904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000591A MX2024000591A (es) | 2021-07-13 | 2022-07-12 | Metodos de tratamiento de enfermedades neurologicas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240309089A1 (https=) |
| EP (1) | EP4370153A4 (https=) |
| JP (1) | JP2024527401A (https=) |
| KR (1) | KR20240042443A (https=) |
| CN (1) | CN117999096A (https=) |
| AU (1) | AU2022310081A1 (https=) |
| CA (1) | CA3225077A1 (https=) |
| MX (1) | MX2024000591A (https=) |
| WO (1) | WO2023284710A1 (https=) |
| ZA (1) | ZA202400405B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3710471A1 (en) * | 2017-11-16 | 2020-09-23 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| WO2024197258A1 (en) * | 2023-03-23 | 2024-09-26 | Klaritos, Inc | Methods of treating alzheimer's disease |
| WO2025190311A1 (en) * | 2024-03-12 | 2025-09-18 | Sinomab Bioscience Limited | Method of identifying anti-siglec antibodies possessing cis-trans converter properties, anti-siglec antibodies and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US9066928B1 (en) * | 2012-12-04 | 2015-06-30 | University Of Kentucky Research Foundation | Method, composition, and kit useful for treatment of alzheimer's disease |
| AU2014305658A1 (en) * | 2013-08-05 | 2016-02-11 | St. Vincent's Institute Of Medical Research | An antibody therapy for amyloid beta disease |
| WO2017196432A1 (en) * | 2016-05-12 | 2017-11-16 | La Jolla Institute For Allergy And Immunology | Compositions and methods for diagnosing and treating neurodegenerative disease |
| EP3867280A4 (en) * | 2018-10-18 | 2022-11-09 | Sinomab Bioscience Limited | METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS |
| ES2821599A1 (es) * | 2019-10-24 | 2021-04-26 | Univ Del Pais Vasco / Euskal Herriko Unibertsitatea | Compuestos y metodos para el tratamiento de la enfermedad de alzheimer |
-
2022
- 2022-07-12 MX MX2024000591A patent/MX2024000591A/es unknown
- 2022-07-12 US US18/578,300 patent/US20240309089A1/en active Pending
- 2022-07-12 CA CA3225077A patent/CA3225077A1/en active Pending
- 2022-07-12 EP EP22841346.4A patent/EP4370153A4/en active Pending
- 2022-07-12 KR KR1020247004608A patent/KR20240042443A/ko active Pending
- 2022-07-12 WO PCT/CN2022/105077 patent/WO2023284710A1/en not_active Ceased
- 2022-07-12 JP JP2024501831A patent/JP2024527401A/ja active Pending
- 2022-07-12 AU AU2022310081A patent/AU2022310081A1/en active Pending
- 2022-07-12 CN CN202280061890.XA patent/CN117999096A/zh active Pending
-
2024
- 2024-01-11 ZA ZA2024/00405A patent/ZA202400405B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240042443A (ko) | 2024-04-02 |
| JP2024527401A (ja) | 2024-07-24 |
| WO2023284710A1 (en) | 2023-01-19 |
| EP4370153A1 (en) | 2024-05-22 |
| ZA202400405B (en) | 2025-03-26 |
| EP4370153A4 (en) | 2025-05-07 |
| CA3225077A1 (en) | 2023-01-19 |
| CN117999096A (zh) | 2024-05-07 |
| AU2022310081A1 (en) | 2024-02-01 |
| US20240309089A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000591A (es) | Metodos de tratamiento de enfermedades neurologicas. | |
| DE60045427D1 (de) | Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen | |
| CR8095A (es) | Anticuerpos humanizados que reconocen el cuerpo beta amiloideo | |
| MXPA03010911A (es) | Anticuerpos contra ngf para el tratamiento de varios desordenes. | |
| PL1613347T3 (pl) | Humanizowane przeciwciała rozpoznające peptyd beta amyloidowy | |
| AU2782499A (en) | Isolated stromal cells for use in the treatment of diseases of the central nervous system | |
| EA200602015A1 (ru) | Гуманизированные антитела, распознающие бета-амилоидный пептид | |
| ATE330631T1 (de) | Antikörperfragmente zur lokalen behandlung von augenerkrankungen | |
| DK1385864T3 (da) | Anti-VEGF-2-antistoffer | |
| EA200501560A1 (ru) | Предотвращение и терапия амилоидогенной болезни | |
| MXPA05003621A (es) | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. | |
| MY139983A (en) | Humanized antibodies that recognize beta amyloid peptide | |
| BRPI0514199A (pt) | método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 | |
| MX2025001590A (es) | Proteinas y conjugados de union al receptor de transferrina | |
| PH12023550032A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| JOP20210324A1 (ar) | مشتقات من 2h-indazole واستخدامها في علاج مرض | |
| MY208067A (en) | Tubulysins and protein-tubulysin conjugates | |
| MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| SA521430793B1 (ar) | أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر | |
| AU2003291287A8 (en) | Apkc isoforms in nervous system disorders and cancer | |
| EP4370131A4 (en) | METHODS FOR TREATING ALZHEIMER'S DISEASE | |
| CR20250142A (es) | Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados (divisional exp. 2022-0531) | |
| CR20240265A (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
| ATE437641T1 (de) | Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis | |
| Arenas et al. | Oncology: management of elderly cancer patients |